Investors and analysts reacted immediately to Novo's revelation. The price of Novo's common stock declined dramatically. From ...

JPMorgan lowered the firm’s price target on Novo Nordisk (NVO) to DKK 1,000 from DKK 1,050 and keeps an Overweight rating on the ...

Trump's threat of imposing a tariff on Denmark over desires to acquire Greenland has caught the attention of one of the ...

Donald Trump 's renewed push to take control of Greenland is setting off a high-stakes showdown with Denmark, a small country ...

Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter despite missing the company’s ...

The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S . Shareholders who purchased shares of NVO ...

Don't want to spend a fortune and break the bank on investing in growth stocks? The ones listed here all cost less than $100.

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

An advocacy group criticizes Hims & Hers Health for allegedly misleading Super Bowl ad promoting weight loss products, violating FDA regulations. Read more here.

Bernstein research firm maintained a positive outlook on Eli Lilly (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $1,100.00. The endorsement comes amid a complex narrative ...